Rune is a clinical phase development company with several new, innovative products in its pipeline.  Research and Development focuses on Mental Health and Neurological conditions ranging from Severe Schizophrenia through to Localised Pain.

We are pushing back the boundaries of care, using ground-breaking development techniques to bring multi-targeted products to market addressing several aspects of treatment each time, for example, offering improvements in side effects and adherence, or clinical efficacy and tolerability. 

Combining cutting-edge formulation technology with electronic, digital care processes to provide best-in-class products.

Our belief is that new treatments should aim to be the best that we can achieve, not creating just a novel chemical entity in a standard, unpleasant tablet format; but rather formulated to be the most tolerable approach, encouraging best adherence to ensure regular dosing and best response in the real world.

Rune Group develops products for rare diseases – utilising the Orphan Drug Approval route at the FDA in the USA and similar Approval routes around the world.